Parrot helps Makers For Life to design the MakAir respirator

Parrot is proud to support the French medical profession facing the Covid-19 by sharing the MakAir open source respirator project with its experience in engine design and integration.

 

The engine is an essential and very demanding part of any ventilation device: constant power, controlled vibrations, sufficient reliability and endurance to allow 24/24 operation for 6 weeks.

 

Our expertise allows us to offer today 500 engines that perfectly meet these criteria, for the launch of the MakAir project, which is both ambitious, simple and modular.

 

Ultimately, as part of industrialization in France, Parrot will have made 5,000 engines available to the project.

The genesis of the MakAir project

 

The magnitude of the Covid-19 pandemic has disrupted the entire medical chain worldwide. In particular, it highlighted a shortage of artificial respirators, which are essential for intubating the most severe patients for one to three weeks.

 

In France, a first project coordinated by Air Liquide aimed to increase the production of artificial respirators from 200 to 10,000 per year, starting in May 2020. This project brings together many manufacturers.

 

A second nonprofit project has spurred initiatives to create a simplified artificial respirator from standard components to help alleviate the shortage as soon as possible. Quentin Adam of the Makers For Life collective, in collaboration with Professors Antoine Roquilly and Pierre-Antoine Gourraud of the Faculty of Medicine of Nantes, and Erwan L'Her, Head of the Intensive Medicine and Care Department of the Brest CHU, proposed a concept innovative simplified artificial respirator, based on a software regulation of inspirationexpiration, directly from the pneumatic system (and not from electromechanical ventilators). This architecture makes it possible to simplify the very complex management of the lungs under Covid-19, to dispense with multiple measurements and displays, and to use fans and standard components.

The Nantes developer team turned to the CEA for the industrialization of this concept, which had already been the subject of a proof of concept at the Brest University Hospital.

 

The financing of the project until its industrialization was provided by "public money" (direct and indirect funding, made available to resources):

– by the foundation of the University of Nantes, the CHUs of Nantes and Brest, with the support of Pays-de-Loire and the community of Nantes
– by CEA with the support of the Auvergne-Rhône-Alpes region

 

Versions

 

Version 0 (<10 units)
Proof of concept

 

Prototype allowing to carry out architecture validation tests, to verify operating parameters, software, and to carry out initial tests on animals.

 

Operating objective: at least 4 days

 

Version 1.x (<500 units)
Pre-industrial product for qualification

 

Product allowing to conduct patient trials with BOM of reliable and biocompatible components.

 

Operating objective: 80% of machines> 3 weeks

Version 2.x (> 500 - 5000 units)
Industrial product

 

Industrialized product with secure supply chain, with quality control of components (FMEA) and assemblies.

 

For more information:
https://makair.life/
https://twitter.com/Makair_fr